

# Hypothalamic obesity, Hyperphagia & Hyperinsulinaemia: time for a paradigm shift in assumptions?

Hoong-Wei Gan<sup>a,b</sup>, Clare Leeson<sup>c</sup>, Helen Aitkenhead<sup>c</sup>, Helen Spoudeas<sup>b</sup>, Meहुल Dattani<sup>a,b</sup>

Great Ormond Street Hospital for Children NHS Trust

<sup>a</sup>Genetics & Genomic Medicine Programme, UCL Institute of Child Health, UK | <sup>b</sup>The London Centre for Paediatric Endocrinology & Diabetes, Great Ormond Street Hospital for Children NHS Foundation Trust, UK | <sup>c</sup>Department of Chemical Pathology, Great Ormond Street Hospital for Children NHS Foundation Trust



## Background

- Hypothalamic obesity (HyOb) is a syndrome of inexorable, treatment-resistant, morbid obesity seen after congenital (e.g. septo-optic dysplasia (SOD)) and acquired (e.g. suprasellar tumours) hypothalamic damage.
- HyOb is commonly associated with other features of the hypothalamic syndrome (panhypopituitarism, autism, sleep disturbances, temperature dysregulation).
- Its pathophysiology is poorly understood but often attributed to hyperphagia and increased caloric intake.
- Unclear whether hyperinsulinaemia is the cause or effect in HyOb.

### Objectives

- To determine the frequency of hyperphagia in HyOb in comparison to simple obesity
- To examine the associations between hyperphagia and hyperinsulinaemia in HyOb and simple obese patients

## Methods

- Multi-way case-control study of four subcohorts:**
  - Hypothalamic obese (HyOb, BMI > +2 SDS) – congenital (SOD) vs. acquired (suprasellar tumour)
  - Hypothalamic lean (HyLean, BMI ≤ +2 SDS) – congenital (SOD) vs. acquired (suprasellar tumour)
  - Simple obese
  - Lean controls
- Dependent variables:** Dykens' Hyperphagia Questionnaire Scores (DHQS), fasting and 2-hour oral glucose tolerance test (OGTT)-stimulated glucose and insulin indices
- Statistical analyses (SPSS v 22):** Non-parametric Mann Whitney-U, Kruskal Wallis one-way ANOVA and  $\chi^2$  tests

## Results

### Baseline characteristics


	HyOb		HyLean		Simple obese (20)	Lean control (14)
	SOD (14)	Tumour (17)	SOD (13)	Tumour (3)		
<b>Age**</b>	14.5 (10.2-16.3)	14.2 (9.1-18.0)	11.7 (7.3-12.3)	14.5 (8.1-14.5)	11.7 (8.9-13.8)	10.0 (6.1-12.8)
<b>Female</b>	6 (42.9%)	12 (70.6%)	7 (53.8%)	2 (66.7%)	10 (50.0%)	3 (21.4%)
<b>Tanner stage*</b>	2 (1-4)	3 (2-5)	1 (1-3)	1 (1-2)	2 (1-3)	1 (1-3)
<b>Height SDS</b>	-0.4 (-0.9-0.8)	-0.9 (-1.9-1.5)	-1.8 (-2.0--0.9)	-0.9 (-2.6--0.4)	0.8 (-1.2-1.1)	-1.0 (-2.4-2.0)
<b>Weight SDS***</b>	2.2 (1.9-2.7)	1.8 (1.4-2.6)	0.0 (-1.0-0.5)	0.9 (-1.1-1.3)	2.5 (1.6-3.5)	0.0 (-1.3-1.1)
<b>BMI SDS***</b>	2.8 (2.6-3.2)	2.6 (2.4-3.0)	1.0 (0.6-1.8)	1.6 (0.7-1.9)	2.8 (2.4-3.2)	0.3 (-1.0-1.3)

NS


NS

\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$

### Hyperphagia is not unique to hypothalamic obesity



### Hyperinsulinaemia is not more severe in hypothalamic obesity compared to simple obesity



	HyOb	HyLean	Simple Obese	Normal Lean
<b>HOMA-IR***</b>	2.8 (1.3-4.9)	1.1 (0.6-1.6)	2.5 (1.4-4.0)	0.8 (0.0-1.0)
<b>Matsuda- ISI***</b>	3.6 (1.8-4.9)	6.3 (4.0-11.8)	3.1 (2.0-4.9)	8.7 (6.8-58.8)
<b>AUC/BMI</b>	3.5 (2.6-6.6)	3.5 (2.2-5.1)	4.3 (3.4-6.0)	2.4 (1.1-3.4)

\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$

- Fasting insulin, HOMA-IR and Matsuda-ISI positively correlated with DHQS and subscores (all  $p < 0.05$ ) but not when corrected for BMI
- Autism ( $p < 0.05$ ), learning difficulties ( $p < 0.05$ ) and sleep disturbances ( $p < 0.01$ ) associated with hypothalamic damage but not HyOb
- 6 (11.8%) and 1 (2.0%) of 51 obese patients had impaired glucose tolerance (IGT) and frank type 2 diabetes respectively

## Conclusions

- Hyperphagia not unique to HyOb and present in simple obesity
- Hyperinsulinaemia is a function of BMI and therefore unlikely to be primary driver of weight gain in HyOb
- The significant prevalence of IGT and type 2 diabetes in all obese children may indicate need for routine screening

References 1. Lustig RH et al. J Clin Endocrinol Metab 2003; 88:2586-92. 2. Dykens EM et al. Obesity (Silver Spring) 2007; 15:1816-26. 3. Matsuda M et al. Diab Care 1999; 22:1462-70.

